Faricimab for diabetic macular edema in South Asian patients
Part of Eyes & vision, Hormones & metabolism clinical trials.
This study tests a drug called faricimab (an injection into the eye) for treating diabetic macular edema, a condition where fluid builds up in the retina and causes vision loss. It is specifically for people of South Asian origin and aims to see how well and how long the treatment works and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to identify as South Asian (Indian, Pakistani, Bangladeshi, or Sri Lankan).
- You must have been diagnosed with type 1 or type 2 diabetes.
- You should have diabetic macular edema (swelling in the center of the retina) that is causing reduced vision.
- If you are new to treatment, your vision should be between 6/12 and 6/120 (moderate to severe vision loss). If you've had treatment before, it must have started within the last 3 years and you must have had a recurrence of swelling.
- Women who can become pregnant must agree to use birth control during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This study tests a medication called faricimab, given as eye injections over a long period, for people with a specific type of wet age-related macular degeneration. The goal is to see if this treatment can help maintain or improve vision over time.
This study observes the effects of a drug called faricimab (given as eye injections) on people with wet age-related macular degeneration (AMD), a condition causing rapid vision loss from abnormal blood vessels leaking fluid in the back of the eye. It aims to see how well the drug works when given in a specific schedule and to monitor safety and outcomes over time. This is an observational study, so you would receive the treatment as part of your normal care, and the research team will collect data.
This trial tests whether faricimab, an eye injection for certain eye conditions, affects kidney function in people with diabetes. It is for those with diabetic macular edema, wet age-related macular degeneration, or macular edema from a vein blockage, who are already taking kidney-protective medications.
This trial tests a new eye drop-free injection medication called faricimab for people with wet age-related macular degeneration who haven't improved enough on standard anti-VEGF shots. The goal is to see if it can reduce fluid and improve vision better than usual treatments.
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.